Toxicity-management decision support for nurses and pharmacists
Give the nurses and pharmacists who take patients' calls a tool that walks them through recognising and managing side effects of modern cancer drugs, including when to escalate.
Immunotherapy and targeted therapy toxicities are managed by triage nurses and pharmacists who may see a given drug rarely. Guideline-based toxicity algorithms (ESMO, ASCO, SITC) exist as tables. Encoding them as decision support integrated with ePRO alerts, with drug-specific pathways and escalation triggers, would standardise management and shorten time to steroids or hospital review for serious immune-related events.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
- Not enough oncologists, nurses, pathologists, physicists · The number of people with cancer is rising faster than the workforce trained to treat them.
Pages like this
not linked directly; found by shared links- IdeaCredentialed diaspora oncologists staffing remote tumour boards for home-country hospitals
Shares Not enough oncologists, nurses, pathologists, physicists, Knowledge reaches practice too slowly.
- IdeaProject ECHO tele-mentoring for district clinicians managing cancer
Shares Not enough oncologists, nurses, pathologists, physicists, Knowledge reaches practice too slowly.
- IdeaTolerability as a co-primary endpoint with its own label claim
Shares Immune-related adverse events (irAEs), Toxicity and quality of life are undervalued.
- IdeaDefine tolerability endpoints as rigorously as efficacy endpoints
Shares Immune-related adverse events (irAEs), Toxicity and quality of life are undervalued.
- IdeaMicro-learning pushed to community oncologists within 30 days of a practice change
Shares Not enough oncologists, nurses, pathologists, physicists, Knowledge reaches practice too slowly.
- IdeaQuality-adjusted survival reported in every trial publication and label
Shares Knowledge reaches practice too slowly, Toxicity and quality of life are undervalued.
- IdeaOffline decision support for generalists treating common cancers in low-resource settings
Shares Not enough oncologists, nurses, pathologists, physicists, Knowledge reaches practice too slowly.
- IdeaPredict immune side-effects before they happen and pre-empt them
Shares Immune-related adverse events (irAEs), Toxicity and quality of life are undervalued.